Background and Aim: The eradication rate of Helicobacter pylori (H. pylori) has been declining over the past decades. A rescue plan is needed for increasing populations with treatment failure. However, the optimum second-line eradication regimen remains inconclusive. We conducted a network meta-analysis to assess the comparative effectiveness of second-line H. pylori eradication therapies and determine the optimum regimen. Methods: We searched electronic databases from January 2005 to February 2018 for randomized controlled trials assessing the effectiveness of second-line regimens in patients with persistent H. pylori infection after first-line treatment. Bayesian network metaanalysis was performed to combine the direct and indirect evidence and to investigate the rank order of second-line therapies. We also appraised the quality of evidence using Grading of Recommendations Assessment, Development, and Evaluation guidance. Results: Twenty-six trials with 3628 participants who received second-line eradication therapy were identified. All regimens showed pooled eradication rates < 90%. Compared with 7-day triple therapy, quinolone-based (odds ratio [OR] 4.29, 95% credible interval [CrI] 1.67-12.12, surface under the cumulative ranking [SUCRA] 0.95), non-quinolonebased bismuth-containing quadruple therapies for 10 days or more (OR 2.25, 95% CrI 1.10-4.62, SUCRA 0.78), and sequential therapy (OR 2.91, 95% CrI 1.16-7.65, SUCRA 0.66) showed significantly higher effectiveness. Overall, regimens with longer duration demonstrated higher eradication rates but higher rates of adverse events. More adverse events were reported in those patients treated with concomitant therapy. Conclusions: Quinolone-based bismuth-containing quadruple therapies for 10 days or
Introduction
Helicobacter pylori (H. pylori) infection is responsible for the majority of cases of chronic gastritis, peptic ulcer, gastric marginal zone/mucosa-associated lymphoid tissue lymphoma, and gastric cancer. 1 Treatment of H. pylori leads to upper gastrointestinal disorder symptom abolition, complication reduction, and relapse prevention. An ideal regimen for H. pylori should have a consistent treatment success rate higher than 90% on intention-to-treat analysis. 2 However, the cure rate for major standard triple therapy has fallen below this level. It is recommended that standard triple therapy should only be used in areas with known low clarithromycin resistance (< 15%) and in patients without previous history of macrolide exposure. [3] [4] [5] The reasons for decreasing treatment success include antibiotic resistance, poor compliance, obesity, smoking, low gastric pH, reinfection, and CYP2C19 polymorphisms that affect proton pump inhibitor metabolism. 6 Among these, the increasing antibiotic resistance rates due to overconsumption of antibiotics worldwide have been suggested as the most important factor. 5, [7] [8] [9] While exploring an optimum first-line therapy for H. pylori infection, there is a need to develop a rescue plan as more regimens for H. pylori are prescribed and antibiotic resistance rises. The prevalence of secondary resistance of H. pylori strains to clarithromycin, metronidazole, levofloxacin, as well as dual resistance, in patients with failed first-line treatment is significantly higher when compared with the total population. 10, 11 Thus, the antibiotics initially used and secondary resistance affect the introduction of a rescue therapeutic strategy.
Bismuth-containing quadruple therapy for 14 days has been recommended as the second-line therapy when patients fail to respond to standard triple therapy, 12 and levofloxacin-containing therapy for 14 days has been recommended as the second-line therapy when patients fail to respond to clarithromycin-containing treatment or bismuth quadruple therapy. 13 However, these two therapies, with cure rates of 76% and 78%, respectively, fail to reach the ideal 90% success rate.
For determining the efficacy of second-line eradication regimens, randomized controlled trial (RCT) provides the highest level of evidence. However, most previous RCTs have been limited by small numbers of observations and inconsistent results. To date, most reviews of second-line therapy for H. pylori eradication have been carried out via traditional meta-analysis. [14] [15] [16] [17] [18] However, traditional meta-analysis cannot provide effective estimates for drugs that lack head-to-head comparison. As there are many available second-line treatments for H. pylori infection, identifying the optimum therapy is of major concern. Bayesian network meta-analysis (NMA) strengthens inference by combining direct and indirect evidence to estimate the relative effectiveness and rank order across multiple different interventions. Thus, it allows for better generalization and provides useful information for clinical decision-making. 19, 20 Previously, we performed an NMA for optimal first-line H. pylori eradication therapy. 21 In this study, we implemented a systematic review and NMA of RCTs to compare the relative effectiveness of seven H. pylori second-line therapies and to determine the most favorable regimen.
Methods
Search strategy and study selection. We conducted a search of PubMed, EMBASE, and Cochrane Central Register of Controlled Trials for reports published from January 2005 to February 2018. (See Appendix S2 for full search strategy.) No language or publication status restrictions were imposed. We also manually searched references of related reviews. The study protocol was registered online (PROSPERO registry-CRD42015026102). This study was performed according to the PRISMA guidelines (Table S6) . 22 Two investigators checked titles and abstracts independently. Full texts were obtained and screened except for those publications deemed irrelevant. Disagreements were reconciled by discussion with a third reviewer. RCTs that evaluated the eradication rates of second-line H. pylori treatment (with previous failure of only one time treatment) in adult patients (aged 18 years or above) were included. Studies without full text, non-RCTs, case series, case reports, conference abstracts, letters, and workshop presentations were excluded. Persistent H. pylori infection was defined as positive result on at least one of the standard detection methods (13C-Urea breath test, rapid urease test, stool antigen detection, histological examination, bacterial culture, and immunohistochemistry) at least 4 weeks after first-line treatment. 23 To prevent the treatment effect of previous antibiotics, we excluded publications with washout period of antibiotics shorter than 4 weeks. We also excluded trials in which recruited patients were allergic to antibiotics or presented with severe comorbidities, as well as those that included non-mainstream interventions (histamine-2 receptor antagonists and dual therapy) or regimens containing probiotics or herbs. Studies that did not randomly assign second-line treatments (e.g. cross-over study) or with small sample sizes (≤ 30 in each arm) were excluded.
Data extraction. Two reviewers independently extracted the data from the included RCTs to a standardized worksheet, such as characteristics of studies and patients, details of first-line and second-line treatments, methods of infection diagnosis and outcome detection, eradication rate, washout period of antibiotics, and side effects. Disagreements were resolved by consensus.
Referring to the latest guidelines and clinical practices, treatments were classified into seven groups: triple therapy for 7 days (TT-7), triple therapy for more than or equal to 10 days (TT ≥ 10), non-quinolone-based quadruple therapy for 7 days (non-Q-BQT-7), non-quinolone-based quadruple therapy for more than or equal to 10 days (non-Q-BQT ≥ 10), quinolone-based quadruple therapy for more than or equal to 10 days (Q-BQT ≥ 10), sequential therapy (ST), and concomitant therapy (CT) (see Table S1 for full regimens). Regimens of the same type, but with different dosages, were grouped together as one comparator. 24 We also extracted data on second-line treatments from a study that combined different lines of rescue therapies. 25 We excluded studies in which eradication rate of second-line therapy could not be derived from the combined rescue therapies. [26] [27] [28] [29] If a study included mainstream and non-mainstream regimens, only data on mainstream regimens were collected. 30 Statistical analysis. (The details of statistical analysis were depicted in Supporting Information).
First, we performed pairwise meta-analyses of direct comparisons to pooled odds ratios (ORs) using DerSimonian and Laird random effects model. 31 To estimate the heterogeneity between studies, we conducted Cochran's Q test and I 2 statistic. Small study effect was examined via Egger's test and visual inspection of funnel plots. 32, 33 To synthesize the data of direct and indirect comparisons, as well as to rank the effectiveness of different treatment groups, we performed an NMA in a Bayesian framework 34 and explored the effect sizes with non-informative priors. We presented the rank order of comparators by surface under the cumulative ranking (SUCRA) probabilities. 35 In addition, we assessed the network inconsistency by calculating the equality of direct and indirect evidence within each loop. An important assumption of NMA is transitivity. Obvious inconsistency represents the violation of assumption of transitivity. 36 To determine the possible bias of increasing antibiotic resistance over time, we performed a subgroup analysis to explore the rank order of the comparators in two time periods (2005-2010 and 2011-2018) . We also conducted sensitivity analyses to investigate the source of heterogeneity. Non-Asian studies and the studies that compared non-quinolone-based triple therapies as second-line treatment were excluded a priori.
Analyses were carried out with R 3.3.3 (metafor 2.0-0) 37 and WinBUGS software V.1.4.3 (NMA) (MRC Biostatistics Unit, Cambridge, UK).
Risk of bias assessment and appraisal of the quality of evidence. Two reviewers assessed the quality of each study and evidence using Cochrane Risk of Bias tool and GRADE (Grading of Recommendations Assessment, Development, and Evaluation) guide, respectively.
38,39 A third reviewer was consulted when there was a disagreement. To identify the risk of selection, attrition, and reporting bias in each study, the following domains were evaluated: study randomization, concealment of allocation, blinding of allocation (physicians, subjects, and operators), complete follow up, and reporting of outcomes. Each domain was classified as low risk, high risk, or unclear. Detailed methodology regarding GRADE guide is shown in Table S4 .
Role of the funding source. This work was supported in part by the National Health Research Institutes (CA-106-PP-37). The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results Figure 1 is the flow diagram for the inclusion of studies. Of the 3582 reports identified, 3396 were excluded after screening the title and abstract. Of the remaining 186 articles, 26 studies were included for data extraction and further analyses.
The major characteristics and outcomes of included RCTs are listed in Table S1 . In total, 3628 participants received second-line therapies. The average age of the participants was 51.0 years. Overall, 22 of 26 studies were conducted in Asia. Clarithromycin-based triple therapies were prescribed as the firstline treatment in most studies. Figure 2 shows the network of eligible comparisons among the seven second-line eradication therapies. The most common comparison was TT-7 versus non-Q-BQT-7 (six studies). Non-Q-BQT-7 showed predominant pairwise comparisons with other regimens (11 studies), followed by TT-7 (10 studies) and TT ≥ 10 (10 studies). Figure 3 and Figure S1 show the effectiveness of second-line H. pylori treatments evaluated by NMA. To compare the effectiveness of regimens, we defined TT-7 as the reference regimen. The overall effectiveness of regimens is displayed in Figure 4 . From the results of NMA, in addition to the superiorities of Q-BQT ≥ 10, ST, and non-Q-BQT ≥ 10 over TT-7, Q-BQT ≥ 10 was superior to non-Q-BQT-7 (OR 3.77, 95% CrI 1.46-10.44) and TT ≥ 10 (OR 2.58, 95% CrI 1.18-6.14). Therapies of longer duration tended to demonstrate higher effectiveness than those of shorter duration. Non-Q-BQT ≥ 10 was significantly better than non-Q-BQT-7 (OR 1.99, 95% CrI 1.01-3.76) and the OR for the comparison between TT ≥ 10 and TT-7 was 1.66 (95% CrI 0.83-3.40). In terms of pooled eradication rate, regimens with extended duration were more effective than 7-day therapies ( Figure S2 ). However, all regimens showed pooled eradication rates lower than 90%. 
As 22 of the 26 enrolled studies were conducted in Asia, we performed a sensitivity test in which non-Asian studies were omitted. Results of this sensitivity analysis showed that top ranked regimens were Q-BQT ≥ 10 (OR 2.89, 95% CrI 1.30-7.28), followed by ST, non-Q-BQT ≥ 10, CT, TT ≥ 10, non-Q-BQT-7, and TT-7 (Table S2a) . Besides, most of the regimens in the triple therapy groups (TT-7 and TT ≥ 10) were quinolone-based. To further confirm the comparative effectiveness of quinolone-based triple therapies, we conducted a sensitivity analysis in which trials of non-quinolone-based triple therapies in TT-7 and TT ≥ 10 groups were omitted (Table S2b) . Q-BQT ≥ 10 (OR 5.16, 95% CrI 1.78-16.64) remained in first place. Although TT-Q ≥ 10 was upgraded to third place (OR 2.22, 95% CrI 0.87-5.93), its association with reference group remained non-significant.
We also performed subgroup analysis to assess whether older publications had larger effect (Table S3) . There were 11 studies in the first group (2005) (2006) (2007) (2008) (2009) (2010) . Due to the limited number of studies, none of the comparators showed statistical significance. There were 15 studies in the 2011-2018 group. Two regimens, Q-BQT ≥ 10 and non-Q-BQT ≥ 10, showed statistical significance. Figure 3 Cumulative SUCRA ranking curves for the overall efficacy (rankogram). The bars in each diagram represent the possibilities of the respective regimen to be the best, second best to the seventh best. The cumulative ranking probability (%) of each regimen was plotted by curve. The larger the surface is below the cumulative ranking curve, the higher likelihood that the regimen is the best regimen. SUCRA, surface under the cumulative ranking curve. Abbreviations of treatments are shown in Figure 2 . 
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Traditional meta-analysis of included regimens is shown in Figure S3 . The heterogeneity among different comparisons was from mild to severe. There was no visually remarkable asymmetry on funnel plot (Fig. 5) . The Egger's test also showed no significant publication bias ( Figure S3 ). Moreover, significant intransitivity was not observed, as there was no inconsistency in all loops ( Figure S4 ). Due to the limited number of studies, we were not able to assess the distributions of baseline characteristics and potential effect modifiers in all included studies, but studies that presented these figures showed a broadly similar distribution.
Overall and study-level quality assessments are summarized in Figure 6a ,b. Among the seven domains, no study showed high risk of attrition bias, which was defined as a follow-up rate lower than 80%. Many studies presented unclear risks of bias in random sequence generation (34.6%), allocation concealment (73.1%), blinding to physicians and subjects (65.4%), and blinding to outcome assessment (53.8%). Table S4 presents GRADE results for direct analysis, indirect analysis, and NMA for the outcomes of second-line rescue therapy. Most of the head-to-head comparisons were associated with low to very low quality of evidence. For the overall NMA estimates, there was high quality of evidence supporting superiority of ST over TT ≥ 10; moderate quality of evidence supporting the use of non-Q-BQT-7, non-Q-BQT ≥ 10, and Q-BQT ≥ 10; low quality of evidence supporting the use of TT ≥ 10 and very low quality of evidence supporting the use of ST, CT, when compared with TT-7. There was moderate quality of evidence for the association of Q-BQT ≥ 10 with higher eradication rate in comparison with all other regimens except TT ≥ 10 and ST. There was also moderate quality of evidence for non-Q-BQT ≥ 10 and CT with higher odds when compared with non-Q-BQT-7.
Different types of adverse events were reported by trials (Table S5 ). Most adverse events were mild to moderate in severity. Gastrointestinal adverse events were the most common side effects. More non-severe and severe adverse events were reported in patients who received CT. Therapies with shorter duration seemed to exhibit less adverse events.
Discussion
In this study, we provided evidence-based estimates of the comparative effectiveness of seven mainstay treatments for second-line H. pylori eradication. Q-BQT ≥ 10, ST, and non-Q-BQT ≥ 10 were ranked as the top three regimens. Treatments of longer duration were associated with greater effectiveness. In Asian populations, Q-BQT ≥ 10 remained the most favorable second-line regimen for eradicating H. pylori. All included therapies presented suboptimal therapeutic rates (< 90%). Moreover, we showed that regimens with longer duration and more antibiotics, for example, CT, were associated with more adverse events. Most of the adverse events were mild or moderate in intensity. This is the first NMA to provide a comprehensive and systematic comparison of second-line H. pylori eradication therapies. In this study, recent relevant evidence was synthesized to simultaneously compare the effectiveness of major therapies. Within a Bayesian framework, we integrated both direct and indirect comparisons to provide precise estimates. Moreover, our study revealed indirect treatment comparison estimates not previously reported. We assessed the risk of bias using Cochrane risk-of-bias tool and rated the quality of evidence using GRADE guidance. In addition, we provided the review of clarithromycin resistance rate in the countries/areas where the included studies were conducted to serve as a reference upon selecting the optimal second-line eradication therapy (Table S7) .
Critical factors that impact on the effectiveness of eradication regimens include local antibiotic resistance and adherence. Resistance to clarithromycin and fluoroquinolones, which cannot be overcome by augmenting dose and duration, has been increasing rapidly worldwide and has greatly undermined the eradication rate. 2, 40, 41 Current practice guidelines recommend the use of either bismuth-containing quadruple therapy or levofloxacin-containing triple therapy after failure of first-line clarithromycin-based triple therapy. This is based on a meta-analysis that suggested no significant differences between levofloxacin-based triple therapy for 10 days and bismuth-based quadruple therapy. 17 In this study, NMA presented consistent results following the division of eradication therapies according to treatment duration. We found significantly higher effectiveness for Q-BQT ≥ 10 and non-Q-BQT ≥ 10 when compared with TT-7. In contrast, Q-BQT ≥ 10 and non-Q-BQT ≥ 10 were comparable to TT ≥ 10. The superiority of extended duration bismuth-containing quadruple therapy is supported by the incremental prevalence of primary fluoroquinolone resistance. 8 A recent RCT showed that CT-10 was not superior to Our study demonstrated a consistent finding that CT was not significant better than both TT-7 and TT ≥ 10. Moreover, due to higher amount of antibiotics use, CT was associated with higher Figure 5 Comparison-adjusted funnel plot for the eradication effectiveness of second-line H. pylori therapies. The center central line denotes the null hypothesis that there is no difference between respective study-specific effect sizes and comparison-specific pooled effect estimates. The symmetrical distribution of all circles, represented by the angle between dotted lines and central line, reflects the lack of publication bias in this study.
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risk of adverse events. However, the results were derived from 107 patients. Studies with larger sample size on the efficacy and safety of CT are needed. In addition, in a recent prospective cohort study, quinolone-based, bismuth-containing quadruple therapy attained a ≥ 90% eradication rate in patients with failed standard triple therapy, ST, and CT. 43 Moreover, on subgroup analysis, non-Q-BQT ≥ 10 showed no significant difference in comparison with TT-7 in 2005-2010 group while non-Q-BQT ≥ 10 and Q-BQT ≥ 10 demonstrated significantly higher effectiveness than TT-7 in 2011-2018 group. This change may be attributed to the increased resistance to clarithromycin.
Our findings suggested a superiority of regimens with longer duration, which is consistent with the previous literature. TT-7 and non-Q-BQT-7 were the least effective regimens among all comparators while their counterparts with longer duration were associated with higher eradication rates. This trend was consistent with previous meta-analyses. 14, 17 A longer duration of treatment allows antibiotics to eradicate H. pylori in different niches of the stomach. 44 However, we also showed that the longer the treatment course, the higher the adverse event rates.
Our findings showed that the pooled eradication rate of all regimens is below the acceptable level (90%). None of the studies involved susceptibility-guided therapy. Selecting an optimal drug based on sensitivity testing is critical for eradicating an infectious agent. 45 We believe that the rationale of susceptibility-guided treatment is the key concept in treating infectious disease. However, the invasiveness, time-consumption, and technical requirements for endoscopy, H. pylori culture, and molecular evaluation of resistance reduce the practicality of susceptibility-guided treatment. Moreover, the accessibility of these procedures is even lower in some countries where the prevalence of H. pylori infection is high. Therefore, in these areas, a compromise approach to this dilemma is to determine a rank order of favorable therapies and choose the treatment according to the local resistance rate. A well-established system for monitoring the antibiotic resistance patterns is needed.
There are several limitations to our study. First, only mainstream treatments for H. pylori infection were assessed. Histamine-2 receptor antagonists, herbs, and probiotics-containing therapies are seldom used in current clinical practice. The numbers and sample sizes of trials for investigating the effectiveness of dual therapies were small, which precluded comparable ascertainment of the outcome. Second, most of the included trials assessed the effectiveness of second-line eradication regimens after failure of clarithromycin-based triple therapies. Standard triple therapy is not recommended in most regions due to high clarithromycin resistance. Therefore, more studies are needed to confirm the optimal regimen after recommended first-line therapy. Third, severe heterogeneity was exhibited on several comparisons. Diversity of treatment doses and frequencies may account for this heterogeneity. However, there was no inconsistency between direct and indirect comparisons, indicating lack of intransitivity. Fourth, most of the included studies were conducted in Asia. This also reflected the real-world reality of the high disease burden of H. pylori infection in Asia and lack of concerted effort in investigating the favorable regimen in other endemic areas. Finally, we did not perform subgroup analysis based on local antibiotic resistance pattern due to limited information. However, because most studies recruited patients with failed clarithromycin-based triple therapy, clarithromycin resistance was expected.
Conclusions
In conclusion, our study presented a rank order of second-line H. pylori eradication therapies and suggested that bismuthcontaining quadruple therapy is the optimum second-line regimen for H. pylori eradication. Our findings have important clinical implications in guiding regimen choice when combined with local antibiotic resistance patterns, compliance, and cost.
Research in context
We performed systematic review in PubMed, Embase, and the Cochrane library using keywords including "Helicobacter pylori," "Helicobacter infections," "Campylobacter," "salvage therapy," "second line or rescue or salvage," "retreatment," "retreat," "failure," and other search terms to identify articles published from January 1, 2005, to February 2018. The optimal second-line treatment for H. pylori remains controversial. Although bismuth quadruple therapy for 14 days or levofloxacin triple therapy for 14 days has been suggested as salvage regimens, the level of evidence is low to very low quality. Most trials that determined the effectiveness and safety of second-line eradication therapies were small in sample size. Many previous conventional meta-analyses compared two regimens simultaneously only.
Added value of this study. This is the first NMA that investigates the comparative effectiveness and adverse event in a robust manner. We showed that quinolone-based quadruple therapy for 10 days or more was the highest ranked second-line regimen. Therapies with longer duration (more than 10 days) were associated with higher effectiveness. Regimens with more antibiotics (such as concomitant therapy) showed more adverse events. All mainstream therapies were below optimal therapeutic rate (< 90%).
Implications of all the available evidence. We provide systematic evidence for the effectiveness and safety of different second-line H. pylori eradication therapies. This is particularly useful in areas where empirical treatment is more prevalent than antimicrobial susceptibility-guided therapy.
